Blechacz Boris R A, Gores Gregory J
Division of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Clin Liver Dis. 2008 Feb;12(1):131-50, ix. doi: 10.1016/j.cld.2007.11.003.
Cholangiocarcinoma is a primary hepatic malignancy originating from bile duct epithelium. It is the second most common primary hepatic neoplasia, and its incidence has increased within the last 3 decades. Although several risk factors have been identified, especially chronic biliary tract inflammation, most patients with cholangiocarcinoma have no identifiable risk factors. Recent developments in radiologic and molecular diagnostic methods have helped in the diagnosis of this disease. The only curative therapy is surgical resection or liver transplantation. For patients with advanced stage disease, survival remains limited. With growing understanding of the molecular and cellular etiology of this disease, new targeted therapies are being developed.
胆管癌是一种起源于胆管上皮的原发性肝脏恶性肿瘤。它是第二常见的原发性肝脏肿瘤,其发病率在过去30年中有所上升。尽管已经确定了几种危险因素,尤其是慢性胆道炎症,但大多数胆管癌患者没有可识别的危险因素。放射学和分子诊断方法的最新进展有助于该疾病的诊断。唯一的治愈性疗法是手术切除或肝移植。对于晚期疾病患者,生存时间仍然有限。随着对该疾病分子和细胞病因的认识不断增加,新的靶向治疗方法正在研发中。